Latest News in the pharma Industry

Research & Development

Microbix announces new product development program to help combat Zika virus

Microbix announces new product development program to help combat Zika virus

8 Feb 2016

Using its established development platform and unique expertise in virology, Microbix intends to develop and launch a range of products to help combat the Zika virus.

Read more 
Oasmia submits MAA to the EMA for its lead cancer product Apealea

Oasmia submits MAA to the EMA for its lead cancer product Apealea

8 Feb 2016

The indication sought for Apealea is treatment of epithelial ovarian cancer in combination with carboplatin.

Read more 
Affinivax secures additional funding from Gates Foundation to advance its novel pneumococcal vaccine towards clinical trials

Affinivax secures additional funding from Gates Foundation to advance its novel pneumococcal vaccine towards clinical trials

5 Feb 2016

Company achieves key milestones and additional $2.5 million from the Gates Foundation.

Read more 
Vertex receives Complete Response Letter from FDA regarding Kalydeco

Vertex receives Complete Response Letter from FDA regarding Kalydeco

5 Feb 2016

Company plans to meet with FDA to determine appropriate path forward.

Read more 
Selvita opens new research site in Poznan

Selvita opens new research site in Poznan

4 Feb 2016

The initial laboratory space will amount to 5,500 sq. ft, which constitutes nearly 20% increase in Selvita laboratory space, compared to the current state with significant extension possibilities.

Read more 
Bavarian Nordic enters research collaboration to develop MRSA vaccine

Bavarian Nordic enters research collaboration to develop MRSA vaccine

4 Feb 2016

The collaboration will use Exaxion's computer-based technology to discover novel antigens.

Read more 
Teva and AbCellera enter into agreement to discover rare monoclonal antibodies

Teva and AbCellera enter into agreement to discover rare monoclonal antibodies

3 Feb 2016

Agreement further supports Teva’s novel biologics development program.

Read more 
New drugs from Abbvie, Gilead, Intercept and Merck forecast to achieve blockbuster status by 2020

New drugs from Abbvie, Gilead, Intercept and Merck forecast to achieve blockbuster status by 2020

3 Feb 2016

Annual ‘Drugs to Watch’ study spotlights seven emerging blockbusters poised to enter the market in 2016.

Read more 
Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine

Sanofi Pasteur to leverage its strong vaccine legacy in hunt for Zika vaccine

2 Feb 2016

Building on the company's successful history in developing vaccines against similar viruses, most recently the introduction of Dengvaxia against dengue, Sanofi Pasteur is launching a Zika vaccine project.

Read more 
BMS and Pfizer sign collaboration with Portola Pharmaceuticals to develop and commercialize investigational andexanet alfa in Japan

BMS and Pfizer sign collaboration with Portola Pharmaceuticals to develop and commercialize investigational andexanet alfa in Japan

1 Feb 2016

Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban).

Read more 
Aragen Bioscience announces ground breaking on state-of-the-art research facility

Aragen Bioscience announces ground breaking on state-of-the-art research facility

1 Feb 2016

The new research space will add 15,000 sq.ft. to Aragen’s existing laboratories and will double capacity for diverse efficacy studies.

Read more 
BMS and AbbVie receive positive CHMP opinion for investigational antibody, Empliciti, for the treatment of multiple myeloma

BMS and AbbVie receive positive CHMP opinion for investigational antibody, Empliciti, for the treatment of multiple myeloma

29 Jan 2016

Positive opinion based on reduction in the risk of disease progression or death with Empliciti in combination with standard of care regimen for multiple myeloma demonstrated in ELOQUENT-2 study.

Read more